Kidney Cancer

Across 3 health-related quality of life scales, the combination of pembrolizumab plus lenvatinib had similar or better outcomes than sunitinib for patients with metastatic renal cell carcinoma receiving treatment in the frontline.

CancerNetwork® sat down with Viktor Grünwald, MD, PhD, at the 2021 ASCO Annual Meeting to talk about how new data from the CLEAR trial serve to further inform clinicians about lenvatinib and pembrolizumab for first-line renal cell carcinoma.

Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.

Data from the KEYNOTE-564 trial presented at ASCO indicate benefit of pembrolizumab therapy in patients with clear cell renal cell carcinoma who were receiving therapy in the adjuvant setting.

Another installment of Clinical Quandaries is presented by Karen Férez-Blando, MD, and colleagues of a 45-year-old man with a diagnosis of intermediate-risk stage IV clear cell renal carcinoma who develops grade 2 hand-foot skin reaction on sunitinib therapy.

In the advanced treatment setting, an FDA decision has indicated that the combination of pembrolizumab and lenvatinib may soon be available for certain patients with endometrial tumors and renal cell carcinoma.

ONCOLOGY reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.

Around the Practice: High-Risk Renal Cell Carcinoma

The safety and efficacy of experimental combinations of investigational agents are being analyzed as treatment for advanced clear cell renal cell carcinoma as part of a phase 1b/2 umbrella platform study.

CancerNetwork spoke with Eric Jonasch, MD, about the NCCN’s recommendation and how thee multidisciplinary approach will play a role.

Merck announced an interim analysis of pembrolizumab to treat RCC, finding a clinically significant improvement in disease-free survival when compared with placebo.

Sumanta (Monty) K. Pal, MD, evaluated combination regimes, in particular the use of lenvatinib plus pembrolizumab, and what factors are taken into consideration for deciding on treatment.

Data from JAMA Oncology concluded that patients with a high BMI treated with PD-1/PD-L1–based immune checkpoint inhibitors for mRCC have higher overall survival rates than those with a low BMI.

CancerNetwork® sat down with Jeffrey Graham, MD, FRCPC, to discuss the effectiveness of immune checkpoint inhibitors as frontline therapy for non–clear cell renal cell carcinoma

CancerNetwork® sat down with Thomas Hutson, DO, PharmD, to discuss results of the CLEAR trial presented at the recent Genitourinary Cancers Symposium.

Drs Toni Choueiri and Robert J. Motzer highlight various strategies with novel-based therapies being explored to address limitations surrounding the treatment of metastatic renal cell carcinoma.

Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.

Recommendations regarding how to use novel combinations such as lenvatinib and everolimus, or lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.

Treatment-related adverse events to be mindful of when treating patients with metastatic renal cell carcinoma with a TKI/IO regimen, such as lenvatinib and pembrolizumab, in the frontline setting.

Robert J. Motzer, MD, of the Memorial Sloan Kettering Cancer Center, discusses the rationale for studying lenvatinib plus pembrolizumab or everolimus for frontline metastatic renal cell carcinoma treatment and reacts to outcomes of the phase 3 CLEAR study as presented at ASCO GU 2021.

Drs Toni Choueiri and Robert J. Motzer discuss factors that impact their decisions for treatment of metastatic renal cell carcinoma in the first-line setting and highlight their go-to regimens.

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.

Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.

The FDA accepted a new drug application for belzutifan to treat von Hippel-Lindau disease¬–associated renal cell carcinoma and granted it priority review based on response rate results from a phase 2 trial.

Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.

The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.

Based on results of the phase 3 TIVO-3 trial in patients who have previously received at least 2 lines of therapy for renal cell carcinoma, the FDA granted approval to tivozanib for use in this patient population.

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.

Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.